Advertisement

Search Results

Advertisement



Your search for Kieron Dunleavy, MD matches 10 pages

Showing 1 - 10


lymphoma

Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?

Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...

lymphoma

Kieron M. Dunleavy, MD: Update on Primary Mediastinal B-Cell Lymphoma

Kieron M. Dunleavy, MD, of Georgetown University, offers insights into the latest data on treating patients with primary mediastinal B-cell lymphoma: the optimal regimen; whether radiotherapy or stem cell transplants are needed; new information on the biology of the disease; novel agents such as...

Lombardi Comprehensive Cancer Center, Georgetown University Names Kieron Dunleavy, MD, to Leadership Positions in Hematology

Kieron Dunleavy, MD, was appointed Director of Hematology at the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC. He is now also Chief of the Lymphoma Program at Georgetown University. Dr. Dunleavy joined Lombardi/Georgetown earlier this year. He is former Professor...

lymphoma

Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations

Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.

hematologic malignancies
lymphoma
immunotherapy

Promise and Challenges of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: ZUMA-1 Trial Results

Advancing therapeutics and augmenting curability in diffuse large B-cell lymphoma (DLBCL) have been very challenging. Although many novel approaches have offered promise and continue to be developed, we have not yet identified a clearly superior approach to R-CHOP (rituximab [Rituxan],...

lymphoma

Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics

Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.

lymphoma

Important Briefs: Lymphoma Research on Improved Chemotherapy, Biomarker Associations, and Stem Cell Transplant Approaches

The 11th International Conference on Malignant Lymphoma was held June 15–18 in Lugano, Switzerland. More than 3,000 hematologists, clinical oncologists, pathologists, and researchers attended the meeting, which was first convened in 1981. Topics of discussion included lymphoma staging in the new...

lymphoma

Radiation-sparing Dose-adjusted EPOCH-Rituximab for Primary Mediastinal B-cell Lymphoma 

Tumor control is frequently not achieved with standard immunochemotherapy in patients with primary mediastinal B-cell lymphoma, requiring consolidation with mediastinal radiotherapy. However, radiotherapy is associated with serious late adverse effects and is still associated with disease...

lymphoma

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).

lymphoma

NIH Trial Shows Promising Results in Treating Primary Mediastinal B-cell Lymphoma

Patients with primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to the mediastinum, had excellent outcomes, according to clinical trial results.  Until now, most standard treatment approaches for patients with this type of...

Advertisement

Advertisement




Advertisement